The Serum Institute of India said, "Once DCGI (Drugs Controller General of India) gives us permission to restart the trials in India, we will resume the trials."
Representational Image: ReutersAmid report of a resumption of clinical trials for AstraZeneca and Oxford University coronavirus vaccine, Serum Institute of India said it would resume trials only after the permission from Drugs Controller General of India (DGCI), ANI reported today.
The Serum Institute of India said, “Once DCGI (Drugs Controller General of India) gives us permission to restart the trials in India, we will resume the trials.”
Earlier, news agency Reuters reported that AstraZeneca company as saying today that British clinical trials for AstraZeneca and Oxford University coronavirus vaccine have resumed following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so.
(To be updated)
Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.
Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.
